The therapeutic potential of lantibiotics

Innovations in Pharmaceutical Technology

Volumn , Issue 27, 2009, Pages 22-25

  Boakes, Steven ^a   Wadman, Sjoerd ^a  

^a Novacta Biosystems Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTAGARDIN; ANCOVENIN; DURAMYCIN; EPIDERMIN; GALLIDERMIN; LANTHIOPEPTIN; LANTIBIOTIC; MERSACIDIN; MUTACIN; NISIN; POLYPEPTIDE ANTIBIOTIC AGENT; SALIVARICIN; SUBTILIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CYSTIC FIBROSIS; DENTAL CARIES; DIARRHEA; DRUG ABSORPTION; DRUG ISOLATION; DRUG STRUCTURE; HUMAN; MICROBIAL ACTIVITY; NONHUMAN; PHARYNGITIS; SKIN INFECTION; STRUCTURE ACTIVITY RELATION;

EID: 59149091644     PISSN: 14717204     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (9)

1. Castiglione F et al, Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens, Chem & Biol 15, pp22-31, 2008
2. Dawson MJ, The lantibiotics: an underexploited class of natural products with broad potential, Chemishy Today 24(6), pp25-27, 2006
3. Lubelski J et al, Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin, Cell Mol Life Sci 65, pp455-476, 2008
4. Brötz H et al, The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II, Antimicrob Agents Chemother 42(1), pp154-160, 1998
5. Iwamoto K et al, Curvature-dependent recognition of ethanolamine phosopholipids by duramycin and cinnamycin, Biophys J 93, pp1,608-1,619, 2007
6. Capstick DS et al, SapB and the chaplins: connections between morphogenefic proteins in Streptomyces coelicolor, Mol Micro 64(3), pp602-613, 2007
7. Smith L and Hillman JD, Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics, Curr Opin Microbiol 11, pp401-408, 2008
8. Hancock REW and Sahl H-G, Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies, Nature Biotechnology 24(12), pp1,551-1,557, 2006
9. Grasemann H et al, Inhalation of Moli1901 in patients with cystic fibrosis, Chest 131, pp1,461-1,466, 2007